Last reviewed · How we verify
NCT04990141: PREMOM
Molecular Screening Method for Preeclampsia (PREMOM)
trial testing Peripheral blood collection in cases group in Preeclampsia in 9,586 participants. Completed in 27 March 2024.
27 March 2024
Quick facts
| Lead sponsor | iPremom |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 9,586 |
| Start date | 23 September 2021 |
| Primary completion | 27 March 2024 |
| Estimated completion | 27 March 2024 |
| Sites | 15 locations across Spain |
Drugs / interventions tested
- Peripheral blood collection in cases group
- Peripheral blood collection in control group
Conditions studied
- Preeclampsia — all drugs for Preeclampsia →
Sponsor
iPremom
Who can join
18 and older, female only, with Preeclampsia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening consequences are needed. Thus, the detection of women at risk of suffering PE is key to apply preventive and treatment strategies. Recently, the maternal contribution to PE based on defective decidualization has been evidenced and new technical approaches developed to detect circulating biomolecules in blood such as RNA fragments. The main objective of this study is to evaluate the diagnostic precision of the molecular profile from the maternal blood analysed for the early screening of early onset preeclampsia (EOPE).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Maternal plasma cell-free RNA as a predictor of early and late-onset preeclampsia throughout pregnancy.
Castillo-Marco N, Cordero T, Igual M, Muñoz-Blat I, et al · · 2025 · PMID 41115885 · DOI 10.1038/s41467-025-64215-2
Verify or expand the search:
- PubMed search for NCT04990141
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Preeclampsia
Currently open trials in the same condition.
- NCT06953115 — Vagal Stimulation Therapy and Preeclampsia · NA · recruiting
- NCT06333652 — Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders · Phase 2 · recruiting
- NCT07282171 — A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Parti · Phase 1 · recruiting
- NCT07345845 — MR and Inflammation After Preeclampsia · EARLY_PHASE1 · active not recruiting
- NCT07041281 — Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04990141 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by iPremom
- Last refreshed: 25 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04990141.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing